EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes

Tapan M Kadia, Meixian Huang, Naveen Pemmaraju, Hussein A Abbas, Christopher Ly, Lucia Masarova, Musa Yilmaz, Mi-Ae Lyu, Ke Zeng, Tara Sadeghi, Robin Cook, Courtney D DiNardo und 10 weitere

NEJM Evidence · 28.05.2024 · 3 (6)

DOI: 10.1056/evidoa2300362 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift NEJM Evidence, erschienen am 28.05.2024. Verfasst von Tapan M Kadia und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, MD Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Bone Marrow Failure Disorders, Anemia, Aplastic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: An inflammatory bone marrow microenvironment contributes to acquired bone marrow failure syndromes. CK0801, an allogeneic T regulatory (Treg) cell therapy product, can potentially interrupt this continuous loop of inflammation and restore hematopoiesis. METHODS: In this phase 1 dose-escalation study of CK0801 Treg cells, we enrolled patients with bone marrow failure syndromes with suboptimal response to their prior therapy to determine the safety and efficacy of this treatment for bone marrow failure syndromes. RESULTS: We enrolled nine patients with a median age of 57 years (range, 19 to 74) with an underlying diagnosis of aplastic anemia (n=4), myelofibrosis (n=4), or hypoplastic myelodysplasia (n=1). Patients had a median of three prior therapies for a bone marrow failure syndrome. Starting dose levels of CK0801 were 1 × 106 (n=3), 3 × 106 (n=3), and 10 × 106 (n=3) cells per kg of ideal body weight. No lymphodepletion was administered. CK0801 was administered in the outpatient setting with no infusion reactions, no grade 3 or 4 severe adverse reactions, and no dose-limiting toxicity. At 12 months, CK0801 induced objective responses in three of four patients with myelofibrosis (two had symptom response, one had anemia response, and one had stable disease) and three of four patients with aplastic anemia (three had partial response). Three of four transfusion-dependent patients at baseline achieved transfusion independence. Although the duration of observation was limited at 0.9 to 12 months, there were no observed increases in infections, no transformations to leukemia, and no deaths. CONCLUSIONS: In previously treated patients, CK0801 demonstrated no dose-limiting toxicity and showed evidence of efficacy, providing proof of concept for targeting inflammation as a therapy for bone marrow failure. (Funded by Cellenkos Inc.; Clinicaltrials.gov number, NCT03773393.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Marrow Failure DisordersAnemia, AplasticHumansMiddle AgedAgedMaleAdultFemaleBone Marrow DiseasesYoung AdultPrimary MyelofibrosisT-Lymphocytes, Regulatory

Autor:innen und Institutionen

  • Department of Leukemia, MD Anderson Cancer Center, Houston.
  • Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston.
  • Cellenkos Inc., Houston.
  • Kartos Therapeutics, Redwood City, CA.

Zitieren

APA

Kadia, T. M., Huang, M., Pemmaraju, N., Abbas, H. A., Ly, C., Masarova, L., Yilmaz, M., Lyu, M. A., Zeng, K., Sadeghi, T., Cook, R., DiNardo, C. D., Daver, N., Issa, G. C., Jabbour, E., Borthakur, G., Jain, N., Garcia-Manero, G., Parmar, S., …, & Verstovsek, S. (2024). Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evidence, 3(6). https://doi.org/10.1056/evidoa2300362

Vancouver

Kadia TM, Huang M, Pemmaraju N, Abbas HA, Ly C, Masarova L, et al. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evidence. 2024;3(6). doi:10.1056/evidoa2300362

BibTeX
@article{Kadia2024,
  author = {Kadia, Tapan M and Huang, Meixian and Pemmaraju, Naveen and Abbas, Hussein A and Ly, Christopher and Masarova, Lucia and Yilmaz, Musa and Lyu, Mi-Ae and Zeng, Ke and Sadeghi, Tara and Cook, Robin and DiNardo, Courtney D and Daver, Naval and Issa, Ghayas C and Jabbour, Elias and Borthakur, Gautam and Jain, Nitin and Garcia-Manero, Guillermo and Parmar, Simrit and Flowers, Christopher and Kantarjian, Hagop and Verstovsek, Srdan},
  title = {Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes},
  journal = {NEJM Evidence},
  year = {2024},
  volume = {3},
  number = {6},
  doi = {10.1056/evidoa2300362}
}
Kostenlos starten →